Building an AI-Native Company in a Regulated Industry | Marketing In The Now ft. Dilbir Bain

What does it take to build an AI-native company in one of the most heavily regulated industries on the planet? In this episode of Marketing In The Now, David Reske sits down with Dilbir Bain, CEO of Galaxy Pharmaceuticals, a newly licensed 503B outsourcing facility in Albany, New York, that produces sterile injectable medications for hospitals facing drug shortages. Dilbir shares how his team embeds AI into every step of an FDA-governed workflow while keeping a human in the loop as the critical control point, why AI has proven four to six times less expensive than traditional ERP systems, and how the operational savings are being reinvested into terminal sterilization to create real product differentiation. The two also dig into why internal skeptics are essential to building trustworthy AI, what kind of technologists succeed in an AI-first environment, and why speed and quality don't have to be a trade-off.